Semaglutide dosing in the trials
The stomach gives me a practical explanation for the protocols. Gradual exposure was a practical response to a medicine people sometimes struggled to tolerate.
Dose escalation
The STEP gastrointestinal analysis describes adverse events clustering around dose escalation. The STEP studies worked toward a 2.4 mg weekly subcutaneous dose gradually, and most gastrointestinal events were mild or moderate. A smaller starting amount and staged increases were features of those research protocols.
I read that gradual approach as an acknowledgement of the burden of treatment. A trial needs people to be able to remain on the intervention long enough for its benefits to be tested. A target dose printed beside an outcome gives only part of that practical history.
The amounts on this page describe published experiments. Choosing a dose, altering it or deciding how to respond to symptoms requires a prescribing clinician; these pages supply no personal regimen.
Semaglutide half-life
The pharmacokinetic systematic review reports a subcutaneous half-life of 145-168 hours. Half-life is the time for the circulating amount to fall by half. It describes a gradual decline, so an effect need not end abruptly when administration stops.
Semaglutide's chemistry supports that persistence. A structural review describes the change at position 8 that resists the enzyme DPP-4, and the C-18 fatty diacid side chain at position 26 that promotes albumin binding. Albumin is a normal blood protein; binding to it helps slow clearance. The position 34 substitution supports the intended chemical modification.
I enjoy tracing that useful property to its material origin. The molecule was engineered to remain available much longer than native GLP-1. That persistence also makes a simple on/off picture of treatment inadequate.
Oral semaglutide absorption
The pharmacokinetic review reports approximately 89% bioavailability for subcutaneous semaglutide and about 0.8-1% for the oral formulation. Bioavailability is the share reaching circulation. Oral semaglutide includes the absorption enhancer SNAC; the formulation has to overcome the difficulty of getting a peptide through the stomach.
PIONEER-1 tested oral doses of 3 mg, 7 mg and 14 mg for type 2 diabetes. OASIS-1 tested a 50 mg daily oral formulation for weight reduction. Those are study treatments with their own populations and purposes. The milligram amounts alone cannot compare exposure across the routes.
The formulation problem concealed inside “a pill instead of an injection” interests me far more than the slogan. The route changes how much reaches the blood, which is why copying a number across formulations would miss the essential pharmacology.